GLP-1 Eligibility Criteria: Clinical Markers & Biomarker Context

Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonist eligibility is determined by multiple clinical factors beyond weight alone, including BMI thresholds, metabolic markers, cardiovascular risk, and medical history. The FDA-approved branded medications (Ozempic, Wegovy, Mounjaro) have specific labeling criteria, but healthcare providers often assess broader clinical context when prescribing.

For patients exploring compounded GLP-1 options, understanding both traditional eligibility markers and emerging biomarker insights can support more informed conversations with qualified providers. This precision-wellness approach integrates metabolic status, genetic predispositions in peptide pathways, and individual health goals into a more comprehensive eligibility picture.

Traditional Clinical Eligibility Criteria for GLP-1 Therapy

Branded GLP-1 medications have established FDA labeling criteria. Ozempic (semaglutide) for type 2 diabetes requires diagnosis; Wegovy (semaglutide) for weight management requires BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities. Mounjaro (tirzepatide) follows similar diabetes and weight criteria. These thresholds represent regulatory standards, not absolute clinical boundaries.

Beyond BMI, providers evaluate HbA1c levels, fasting glucose, blood pressure, lipid panels, and cardiovascular history. Presence of obesity-related conditions—hypertension, dyslipidemia, obstructive sleep apnea—strengthens clinical justification. Age, kidney function, and prior medication responses also inform eligibility assessment and dosing safety.

Metabolic Biomarkers That Contextualize GLP-1 Candidacy

Beyond BMI, metabolic biomarkers provide clinical context for GLP-1 appropriateness. These markers reveal insulin resistance patterns, lipid dysfunction, and inflammation—all treatable pathways that GLP-1 agonists can address. Incorporating biomarker assessment into eligibility conversations supports a more granular understanding of who may benefit most from therapy.

Biomarker	Clinical Significance for GLP-1 Eligibility
Fasting Insulin & HOMA-IR	High levels indicate insulin resistance; GLP-1s improve insulin sensitivity and may support weight loss even at lower BMI thresholds.
HbA1c (>5.7%)	Indicates prediabetes or diabetes; GLP-1s reduce glycemic burden and cardiovascular risk across metabolic spectrum.
Triglycerides & LDL-C	Elevated lipids suggest metabolic dysfunction; GLP-1 therapy often improves lipid profiles independent of weight loss.
hs-CRP & inflammatory markers	Chronic inflammation associates with obesity and cardiometabolic disease; GLP-1s exert anti-inflammatory effects beyond glucose control.
Fasting glucose	Impaired fasting glucose (100–125 mg/dL) identifies cardiometabolic risk; GLP-1s prevent progression to overt diabetes.

Genetic Predispositions in GLP-1 Response Pathways

Individual genetic variation in GLP-1 receptor expression, GIPR signaling, and appetite-regulation genes (MC4R, FTO) influences medication response heterogeneity. Some individuals carry variants associated with greater appetite sensitivity or reduced GLP-1R pathway efficiency, which may inform treatment selection and dosing strategy discussions with providers.

PlexusDx Precision Peptide Genetic Test examines key variants (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that reflect predispositions in these peptide pathways. This genetic context may help inform eligibility conversations and medication selection rationale, though genetic testing should always be interpreted alongside clinical assessment by a qualified provider.

Safety Considerations and Who Should Not Start GLP-1 Therapy

Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastroparesis, and acute pancreatitis. Relative cautions include renal impairment, diabetic retinopathy, pregnancy/breastfeeding, and certain medication interactions. Providers must assess these factors before initiating any GLP-1 regimen.

Common side effects—nausea, vomiting, constipation, dehydration—occur in 30–50% of users and typically diminish over weeks. Serious but rare events include acute kidney injury and pancreatitis. Careful monitoring, dose titration, and patient education reduce risk. Eligibility also requires capacity to tolerate injectable or oral formulations and commit to behavioral support.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that traditional BMI and clinical markers provide only partial insight into GLP-1 suitability. Incorporating biomarker and genetic context may help provide a more nuanced eligibility picture. PlexusDx compounded semaglutide and tirzepatide options allow providers to personalize dosing based on clinical response—a flexibility that complements genetic and metabolic assessment.

The Precision Peptide Genetic Test reveals predispositions in GLP-1 receptor pathways, appetite-regulation genes, and metabolic pathways that may inform medication candidacy conversations. For example, individuals with GIPR variants may respond differently to dual GLP-1/GIPR agonists versus GLP-1-only formulations. Genetic predispositions should be interpreted as contextual information—not predictors of exact medication response—and always discussed with a qualified healthcare provider.

Using genetic and biomarker insights alongside traditional eligibility criteria can support a more informed dialogue with your provider about which compounded GLP-1 option, dosing strategy, and monitoring plan align with your individual metabolic profile and health goals. This precision-wellness approach acknowledges that eligibility and optimal treatment are personal, evidence-informed decisions.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.